Search results
'We're trying to do the right thing.' GSK sets diversity targets, partners with DEI firm to educate...
FierceBiotech· 4 days agoGSK is doubling down on its efforts to make clinical trials more diverse, starting with defined enrollment targets and training its clinical R&D workforce on issues around ...
GSK’s Secret Ingredient
Bloomberg· 5 days agoGet briefed ahead of your morning calls with the latest UK business headlines, key data and market reaction
GSK's experimental drug shows promise in reducing severe asthma attacks
AOL· 5 days agoThe drug, called depemokimab, showed "significant and meaningful reductions" in asthma attacks for patients with eosinophilic asthma, GSK said on Tuesday. This form of asthma ...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals,GSK, PTC Therapeutics and Larimar...
Zacks· 2 days ago(PTCT Quick QuotePTCT - Free Report) and Larimar Therapeutics, Inc...
First Zantac Cancer Case to Go to Trial Ends in Win for Drugmakers
Bloomberg· 2 days agoDrugmakers GSK Plc and Boehringer Ingelheim GmbH persuaded a Chicago jury to reject a woman’s claim...
Potential blockbuster asthma drug met goals in trials, GSK says
Morningstar· 5 days agoGSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than GBP3 billion ($3.8 billion) met their goals. GSK (< ...
WHISTLEBLOWER ALLEGES GLAXOSMITHKLINE LIED ABOUT ZANTAC SAFETY CLAIMS
WFRV 5 Green Bay· 5 days agoValisure, Represented by Wisner Baum, alleges in qui tam suit that GlaxoSmithKline (GSK) lied to the FDA and Federal Government about the ability of its "blockbuster" drug ...
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Zacks· 3 days agoTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
GSK's SWIFT trial anthology shows long-acting treatment reduces asthma attacks
FierceBiotech· 5 days agoIt’s not a double album release, but it’s a close runner-up: the pivotal SWIFT-1 and SWIFT-2 trials have shown that GSK's long acting asthma treatment reduces attacks. Center ...
Exclusive: SR One raises $200M+ for third fund, still with GSK support
Endpoints News· 3 days agoSR One, a life sciences venture capital firm that years ago split from GSK, has raised more than...